FDA orders new vision-loss warning for Ozempic, Wegovy and other weight-loss drugs

The Food and Drug Administration said Monday it is requiring the makers of every GLP-1 drug on the US market, including the blockbuster diabetes and weight-loss medications Ozempic, Wegovy, Mounjaro and Zepbound, to add a new warning about a rare eye condition that can cause sudden and sometimes permanent vision loss.

The drug safety communication, dated Nov. 9, 2026, covers nonarteritic anterior ischemic optic neuropathy, or NAION, a condition caused by reduced blood flow to the optic nerve. It can produce acute, painless vision loss in one eye, and the damage can be permanent; there is no established treatment. The agency said application holders must add the information to the "Warnings and Precautions" section of labeling for the entire drug class, not just for one brand or one active ingredient.

What the data show

The FDA's finding rests on a pooled analysis of 126 randomized clinical trials involving 134,253 patients and roughly 289,000 person-years of drug exposure. Within that pool, reviewers identified 15 probable NAION events — 10 among patients taking a GLP-1 drug and five among those on a placebo, with none among patients on other, non-GLP-1 glucose-lowering medicines. That works out to an incidence of 6.4 cases per 100,000 person-years among GLP-1 users, compared with 3.8 per 100,000 among the comparison group.

A separate retrospective look at real-world insurance and medical-claims data, run through the FDA's Sentinel Initiative postmarket-surveillance system, examined adults with type 2 diabetes from 2019 through 2024 and found a background incidence of 26 to 32 cases per 100,000 person-years. Compared with patients on SGLT-2 inhibitor drugs, the increased risk for GLP-1 users was not statistically significant. Compared with patients on DPP-4 inhibitors, it was, with a hazard ratio of 1.43. The agency was explicit that none of this proves the drugs cause the condition, noting that diabetes itself — along with obesity, sleep apnea and high blood pressure, all common among GLP-1 users — is an established NAION risk factor that makes cause and effect hard to untangle.

A review years in the making

The FDA's action follows a 2024 study in JAMA Ophthalmology that found diabetic patients prescribed semaglutide — the active ingredient in Ozempic, Wegovy and Rybelsus — were about four times as likely to be diagnosed with NAION as similar patients not on the drug. That paper prompted European regulators to move first. The EU's Pharmacovigilance Risk Assessment Committee concluded in June 2025 that NAION is a "very rare" side effect of semaglutide, affecting up to 1 in 10,000 patients, and recommended it be added to European product labeling.

The FDA's version announced Monday goes further than any of those, applying to essentially the entire US GLP-1 market: Byetta, Victoza, Trulicity, Saxenda, Xultophy, Soliqua, Ozempic, Rybelsus, Wegovy, Mounjaro and Zepbound. Cases of NAION have now been reported for every currently marketed drug in the class, the agency said.

A warning reaching a huge share of patients

Because the condition itself is rare, the practical reach of Monday's order comes less from the medical risk than from how many Americans take these drugs. According to a KFF poll fielded last fall, about one in eight US adults — roughly 12% — say they are currently taking a GLP-1 drug for weight loss, diabetes or another condition, with use highest among adults ages 50 to 64. That scale is also why the warning lands directly on two of the world's most valuable drugmakers: Novo Nordisk, which sells Ozempic, Wegovy and Rybelsus, and Eli Lilly, which sells Mounjaro and Zepbound. Thousands of product-liability lawsuits already pending against both companies allege they failed to warn patients that the drugs could cause vision loss.

Novo Nordisk said it continues to believe the available data do not establish a cause-and-effect relationship and that it remains confident in the drugs' overall benefit-risk profile. Eli Lilly said it is carefully evaluating the FDA's requirement and will respond to the agency promptly, adding that it has said previously the evidence does not establish a causal relationship between GLP-1 drugs and NAION.

Dr. Manjot Gill, an ophthalmologist at Northwestern Medicine in Chicago, said the FDA's move was an appropriate step given the data but should not by itself change how most patients use the drugs.

"This is extremely rare, so there's really not a cause for a lot of immediate anxiety," Gill said, adding that patients should not be "overly concerned and anxious and to stop these medications."

Wall Street's early reaction was muted. Analysts at Citi described the FDA's class-wide warning as likely to draw attention but said they expect it to have limited impact on how widely GLP-1 drugs are prescribed, given how established the drugs already are in treating diabetes and obesity.

What happens next

The FDA did not publish a compliance deadline for the label change, and it has not restricted use of any GLP-1 drug or added a boxed warning, the agency's strongest category, which several of the drugs already carry for a separate, unrelated concern about thyroid tumors found in rodent studies. Instead, the agency is directing doctors to counsel patients to report any sudden, painless vision loss in one eye immediately, to refer suspected cases promptly to an ophthalmologist, and to weigh discontinuing the drug in a patient who develops NAION unless its benefits clearly outweigh the risk. Patients who have already had an episode of NAION are advised to discuss with their doctor whether to keep taking the medication.

The agency said its review of the safety signal is ongoing and that it will continue to monitor adverse-event reports and new published research as drugmakers move to update their labeling.